Viatris Inc (VTRS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Viatris Inc Stock (VTRS) Company Profile

Healthcare (1112)

(724) 514-1465

1000 MYLAN BOULEVARD, CANONSBURG

Nächster Verdiensttermin

Neueste SEC-Einreichungen

VTRS's Discussions on Twitter

Vergleichen Sie VTRS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VTRS Viatris Inc	13.21	15.25B	14.33B	-3.79B	1.84B	-3.17
ZTS Zoetis Inc	124.05	54.82B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	16.29	50.36B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	10.46	46.00B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	31.81	36.32B	16.88B	666.71M	251.19M	0.6132
UTHR United Therapeutics Corp	468.94	20.33B	3.08B	1.24B	1.07B	25.61

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-16	Hochstufung	Argus	Hold → Buy
2025-12-09	Eingeleitet	Barclays	Overweight
2025-10-15	Eingeleitet	Truist	Buy
2025-06-06	Eingeleitet	Goldman	Neutral
2024-07-19	Fortgesetzt	Jefferies	Buy
2023-10-23	Herabstufung	BofA Securities	Neutral → Underperform
2023-06-23	Herabstufung	Barclays	Equal Weight → Underweight
2023-04-24	Herabstufung	Barclays	Overweight → Equal Weight
2023-02-17	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2023-01-27	Hochstufung	Jefferies	Hold → Buy
2022-11-10	Hochstufung	UBS	Sell → Neutral
2022-11-08	Hochstufung	Piper Sandler	Underweight → Neutral
2022-10-21	Fortgesetzt	Jefferies	Hold
2022-06-14	Eingeleitet	UBS	Sell
2022-05-10	Herabstufung	Piper Sandler	Neutral → Underweight
2022-03-01	Herabstufung	BofA Securities	Buy → Neutral
2022-03-01	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-06-15	Eingeleitet	Citigroup	Neutral
2021-04-07	Fortgesetzt	RBC Capital Mkts	Outperform
2021-03-08	Herabstufung	Goldman	Buy → Neutral
2021-03-02	Herabstufung	JP Morgan	Overweight → Neutral
2021-02-26	Herabstufung	Wolfe Research	Outperform → Peer Perform
2021-01-05	Eingeleitet	Argus	Hold
2020-12-14	Eingeleitet	Bernstein	Mkt Perform

Alle ansehen

Viatris Inc Aktie (VTRS) Neueste Nachrichten

Finanzdaten der Viatris Inc-Aktie (VTRS)

Viatris Inc (VTRS)

Viatris Inc Stock (VTRS) Company Profile

Vergleichen Sie VTRS mit anderen Aktien

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Viatris Inc Aktie (VTRS) Neueste Nachrichten

Will Viatris Inc benefit from green energy policiesPortfolio Value Report & Free Verified High Yield Trade Plans - baoquankhu1.vn

Viatris Launches Inpefa In UAE As Valuation And Growth Draw Focus - Sahm

Is Viatris (VTRS) Pricing Reflect Its Recent Multi‑Year Share Price Recovery - Yahoo Finance

Viatris (VTRS) Valuation Check After First International Inpefa Heart Failure Launch - Yahoo Finance

Viatris Earnings Preview: What to Expect - Barchart.com

Viatris launches heart failure drug Inpefa in UAE, first outside US - Investing.com Nigeria

Viatris launches heart failure drug Inpefa in UAE, first outside US By Investing.com - Investing.com South Africa

3 Reasons to Sell VTRS and 1 Stock to Buy Instead - Finviz

Viatris Inc. Stock Outperforms Market Despite Losses On The Day - 富途资讯

Viatris Launches Inpefa in United Arab Emirates - marketscreener.com

Viatris Launches Inpefa To Treat Heart Failure In UAE - Nasdaq

Viatris Launches Inpefa, Expanding Its Heart Failure Portfolio And Broadening Presence In Cardiovascular Diseases - TradingView — Track All Markets

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure - PR Newswire

Movement Recap: Is Viatris Inc backed by strong institutional buyingBear Alert & Weekly High Conviction Trade Ideas - baoquankhu1.vn

Biocon Raises Rs 4.15 Billion Via QIP For Biologics Buy - Construction World India

Levels Update: Will Viatris Inc stock hit new highs in YEARJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn

Argus Research Upgrades Viatris (VTRS) - Nasdaq

Biocon Secures Rs 4,150 Cr Through QIP to Buy Out Viatris Stake in Biologics Arm - Medical Dialogues

Viatris stock tests multi-year ceiling after impressive rally - FXStreet

United States Treatment-Resistant Depression Market to grow - openPR.com

Cash offers target up to $450M of Viatris 2026 and 2025 notes - Stock Titan

Viatris (VTRS) Gets a Sell from Bank of America Securities - The Globe and Mail

Biocon Raises Rs 4,150 Cr via QIP Issue - Rediff MoneyWiz

RSI Check: Is Viatris Inc. impacted by rising ratesWeekly Profit Summary & Daily Profit Focused Screening - baoquankhu1.vn

Contact UsCeres CourierViatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation - FinancialContent

Viatris stock steadies in premarket after a 5% jump on JPM conference remarks — what investors watch next - TechStock²

Generic Drugs Market to Hit US$ 942.69 Billion by 2033 | CAGR 7.1% | - openPR.com

Viatris Inc. stock rises Tuesday, outperforms market - MSN

Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight - GlobeNewswire Inc.

What is the earnings history of Viatris IncWeekly Investment Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn

Viatris Stock: Is Wall Street Bullish or Bearish? - MSN

Viatris hits main goals in Phase 3 trial for birth control patch - MSN

Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims - Law360

Viatris Inc. Stock Rises Friday, Outperforms Market - 富途牛牛

Why Analysts See The Viatris (VTRS) Story Shifting With Affordable Medicines And A US$16 Target - Yahoo Finance

Viatris Inc.: Can a Hybrid Pharma Powerhouse Reinvent the Generic Drug Game? - AD HOC NEWS

Goldman Sachs Adjusts Price Target on Viatris to $13 From $12, Maintains Neutral Rating - marketscreener.com

Can Viatris Inc. stock deliver strong Q4 earningsTrend Reversal & Growth Focused Entry Point Reports - ulpravda.ru

How analysts revise price targets for Viatris Inc. (VIA) stockCPI Data & High Conviction Investment Ideas - ulpravda.ru

Does Viatris Inc. (VIA) stock trade below intrinsic value2025 Historical Comparison & Real-Time Volume Trigger Notifications - ulpravda.ru

Viatris Inc. Stock Rises Thursday, Outperforms Market - 富途牛牛

Performance Recap: Why Viatris Inc. stock remains on buy listsMarket Activity Report & Safe Entry Zone Identification - ulpravda.ru

Viatris names veteran executive to lead people and corporate affairs - The Business Journals

Viatris stock hits 52-week high at 12.68 USD By Investing.com - Investing.com South Africa

Viatris stock hits 52-week high at 12.68 USD - Investing.com

Why Viatris Inc. stock remains on buy listsEarnings Trend Report & AI Powered Trade Plan Recommendations - ulpravda.ru

Viatris appoints Lara Ramsburg as chief people and corporate affairs officer - marketscreener.com

Viatris names Lara Ramsburg as chief people and corporate affairs officer - Investing.com Australia

Viatris names Lara Ramsburg as chief people and corporate affairs officer By Investing.com - Investing.com South Africa

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer - Viatris

Viatris Inc.: How a Quiet Generic Drug Giant Is Re?wiring Global Healthcare - AD HOC NEWS

Finanzdaten der Viatris Inc-Aktie (VTRS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie VTRS